Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | LAP3 | P28838 | 4/20 | 0.41 |
| ▸ | ANPEP | P15144 | 5/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.37 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alafosfalin SCHEMBL1582303 | 1.00 | DPP4 (0.48) | DPP4LAP3ANPEPCA12CA1 | |
| Alafosfalin SCHEMBL1582301 | 1.00 | DPP4 (0.48) | DPP4LAP3ANPEPCA12CA1 | |
| Alafosfalin SCHEMBL456724 | 1.00 | DPP4 (0.48) | DPP4LAP3ANPEPCA12CA1 | |
| Alafosfalin SCHEMBL9619892 | 0.98 | DPP4 (0.47) | DPP4LAP3ANPEPCA12CA1 | |
| Alafosfalin SCHEMBL11297483 | 0.98 | DPP4 (0.47) | DPP4LAP3ANPEPCA12CA1 | |
| SCHEMBL11299128 | 0.92 | DPP4 (0.42) | DPP4LAP3ANPEPCA12CA1 | |
| SCHEMBL18919534 | 0.92 | DPP4 (0.42) | DPP4LAP3ANPEPCA12CA1 | |
| SCHEMBL1582769 | 0.92 | DPP4 (0.42) | DPP4LAP3ANPEPCA12CA1 | |
| SCHEMBL1582242 | 0.92 | DPP4 (0.42) | DPP4LAP3ANPEPCA12CA1 | |
| SCHEMBL11296889 | 0.86 | PAX8 (0.40) | DPP4LAP3ANPEPDPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-28 | — | — | US | disclosed |
| WO-2026107208-A1 | COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS | THE METHODIST HOSPITAL (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260125426-A1 | CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-07 | — | — | US | disclosed |
| EP-3958767-B1 | DEVICES FOR DELIVERING THERAPEUTIC MATERIALS TO THE INTERVERTEBRAL DISC | WARSAW ORTHOPEDIC INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | MODEL MEDICINES INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12582455-B2 | Bone material dispensing device | WARSAW ORTHOPEDIC, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260070947-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260070948-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20220160464-A1 | SMART COMPOSITE WITH ANTIBIOFILM, MINERALIZING, AND ANTIINFECTION THERAPEUTIC EFFECTS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-26 | — | — | US | disclosed |
| EP-3395273-B1 | BONE MATERIAL DISPENSING APPARATUS AND METHODS | WARSAW ORTHOPEDIC INC (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3308719-B1 | EXPANDABLE DEVICE FOR TISSUE COLLECTION FROM AN AERODIGESTIVE BODY LUMEN | ADN INT LLC (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3965799-A1 | COMPOSITIONS AND SYNERGISTIC METHODS FOR TREATING INFECTIONS | Bioaegis Therapeutics Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| WO-2022049149-A1 | CHEWABLE FORMULATIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2022-03-10 | — | — | WO | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| EP-3946489-A1 | SMART COMPOSITE WITH ANTIBIOFILM, MINERALIZING, AND ANTIINFECTION THERAPEUTIC EFFECTS | Temple University - Of The Commonwealth System of Higher Education (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2022020752-A1 | LIQUID CRYSTAL SCAFFOLDS AND USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-27 | — | — | WO | disclosed |
| US-4431438-A | HERBICIDES | CIBA-GEIGY CORPORATION (US) | 1984-02-14 | — | — | US | disclosed |
| EP-0010067-A2 | Process for influencing plant growth | CIBA-GEIGY AG (CH) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | ESR1, VDR, POLL | DPP4 73/4885LAP3 1480/4885ANPEP 637/4885 |
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, SLC7A1, SLC6A15 | DPP4 523/4885LAP3 50/4885ANPEP 16/4885 |
| US-20260125426-A1 | CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF | SLC7A1, TAP1, SLC7A5 | DPP4 1103/4885LAP3 385/4885ANPEP 54/4885 |
| US-20260070947-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | SLC7A1, SLC38A7, SLC6A19 | DPP4 710/4885LAP3 139/4885ANPEP 57/4885 |
| US-20260070948-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO | SLC7A1, SLC38A7, SLC6A19 | DPP4 994/4885LAP3 130/4885ANPEP 77/4885 |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | SARS1, NSUN2, NSUN3 | DPP4 150/4885LAP3 2134/4885ANPEP 812/4885 |
| US-12582455-B2 | Bone material dispensing device | BMP2, BMP4, BMP1 | DPP4 1567/4885LAP3 884/4885ANPEP 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.